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Deting Xue, Fangcai Li, Gang Chen, Shigui Yan and Zhijun Pan*Abstract
Background: Whether bisphosphonates affect indirect bone healing is still unclear.
Method: We carried out a comprehensive search strategy. Only randomized controlled trials were included. Two
reviewers independently assessed methodological qualities and extracted outcome data. Analysis was performed
with RevMan 5.2.
Results: Eight eligible randomized controlled trials with 2,508 patients were included. Meta-analysis results showed
that no statistically significant differences were founded in indirect bone healing in short time (within 3 months)
(relative risk (RR) 1.40, relative the control group; 95% CI 0.36 to 5.49) and in long-term (more than 12 months)
postoperation (RR 1.0; 95% CI 0.98 to 1.02) between bisphosphonates infusion groups and control groups. There
were no statistically significant differences of indirect bone healing between early and delay bisphosphonates
administration groups. Bisphosphonates infusion after lumbar infusion surgery could promote bone healing and
shorten fusion time in 6 months postoperation (RR 1.35; 95% CI 1.11 to 1.66).
Conclusion: There was no clinically detectable delay to fracture healing via external callus formation following
bisphosphonates treatment. Considering the benefit aspects of bisphosphonates for osteoporosis treatment, we
recommend bisphosphonates infusion after fracture fixation surgery and lumbar fusion surgery.
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There are two kinds of drugs which affect bone remold-
ing, anabolic and anti-catabolic drugs. Anabolic drugs
influence the osteoblasts and increase osteogenesis [1].
However, the high costs of anabolic drugs limit their
wide applications. So most countries recommend anti-
catabolic drugs as the first line drugs for treating osteo-
porosis, especially bisphosphonates [2]. Bisphosphonates
have an inhibitory effect on osteoclastic bone resorption.
So they have been used in diseases with increased bone
turnover, such as osteoporosis, Paget's disease, and meta-
static bone diseases [3-5]. In theory, bisphosphonates in-
hibit osteoclast-mediated bone resorption which would
prevent bone loss and improve bone strength [6,7]. But
treating patients with bisphosphonates during bone heal-
ing is controversial because osteoclasts are important for
remodeling callus into cortical bone [8]. Several studies* Correspondence: zepzj@163.com
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unless otherwise stated.have addressed the effects of bisphosphonates on indirect
bone healing. The results are inconsistent. Lenehan et al.
[4] found that ethane-1-hydroxy-1,1-diphosphonate inhib-
ited indirect fracture healing in a dose-dependent manner
in mature beagle dogs. In a prospective study, Kim et al.
found that bisphosphonates did not affect intertrochan-
teric indirect fracture healing [3]. A randomized study of
32 postmenopausal women with Colles' fractures showed
that the clodronate increased mineralization of callus [5].
So shall we use bisphosphonates for the patients with
osteoporotic fractures or spinal fusion?
In order to summarize available randomized control tri-
als and make this issue clear, we performed a meta-analysis
of available randomized evidence to evaluate whether
bisphosphonates affect bone healing.Methods and materials
We searched Medline (1966–May 2013), Embase (1980–
May 2013), Science Citation Index (1981–May 2013),
Cochrane Central Register of Controlled Trials (CENTRAL),. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,

















van der Poest et al.
(Netherlands) 2000 [7]
F 18/17 65.7 Distal forearm fractures,
T-score ≤ 2
10 mg alendronate +
500 mg calcium vs.









F 16/16 62 Displaced Colles' fracture;
postmenopausal women




Did not provide BMD, function
Harding et al.
(Sweden) 2011 [14]
M and F 25/21 48.9 Patients with osteoarthritis
or deformity of knee;
age between 35–65 years old
4 mg zoledronic acid vs.




two-thirds of the osteotomy
gap by radiographic
examination
Time to healing; BMD
Nagahama et al.
(Japan) 2011 [12]
M and F 19/17 68.9 Candidated for single-level PLIF;
BMD was less than 70% of
the young adult mean value











M and F 1,065/1,062 Not
reported
Patients within 90 days of
hip fracture repair





persistent pain, bear weight
Radiographic examination
Fracture healing
Kim et al. (Korea)
2012 [3]
M and F 90/0 76.1 Patients with intertrochanteric
fracture; BMD < −2.5
35 mg/week risedronate +






At least two cortices
bridging at the fracture site
Fracture healing,
function
Gong et al. (Korea)
2012 [15]
F 60/0 66.5 Distal radial fractures
treated with plate fixation;
BMD < −2.5
70 mg/week alendronate 2 weeks vs.
3 months after
operation
Bridging by trabeculae or
osseous bone in at least one
cortex as seen on anteroposterior
radiographs and one as
seen on lateral radiographs
Fracture healing,
function; complication
Li et al. (China)
2012 [16]
M and F 41/41 63.73 Patients undergoing TLIF 5 mg zoledronic acid +
calcium 1000 mg/day +
vitamin D 400 IU/day vs.
placebo + calcium



























Figure 1 Selection of study.
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http://www.josr-online.com/content/9/1/45and Cochrane Database of Systematic Reviews (Cochrane
Library, Issue 1, 2013) for randomized clinical trials that
evaluated the effect of bisphosphonates on bone healing.
We also searched unpublished trials and those in progress
using clinical trials repositories, including the National
Institute of Health (May 2013), the National Research
Register (May 2013), and Current Controlled Trials (May
2013). The following terms were used: ‘bisphosphonates’,
‘indirect bone healing,’ and ‘bone formation’. Searches
were not restricted by year of publication or language. Ref-
erence lists of all included studies were scanned to identify
additional potentially relevant studies. Two reviewers in-
dependently screened the titles and abstracts of identified
papers, and full text copies of all potentially relevant stud-
ies were obtained.
Study selection and outcomes
We included studies if they were randomized trials of
bisphosphonates affecting fracture healing, regardless
of the doses and duration of drugs used. No language re-
strictions were applied. We excluded studies that were
not peer-reviewed randomized controlled trials, stud-
ies included patients with diseases that affecting bone
mineral density (BMD) or bone metabolism, such asTable 2 Quality assessment of included studies
Study Randomization Allocated concealment B
van der Poest et al. [7] Unclear Unclear
Adolphson et al. [5] Adequate Adequate A
Harding et al. [14] Adequate Adequate A
Nagahama et al. [12] Adequate Adequate A
Colon-Emeric et al. [13] Adequate Adequate A
Kim et al. [3] Adequate Unclear
Gong et al. [15] Adequate No
Li et al. [16] Adequate Adequate Arenal or adrenal insufficiency, diabetes, and any his-
tory of taking any medication known to affect BMD, such
as corticosteroids.
Bone healing criteria: all of the study used radiographic
examination to evaluate bone healing, but one study [5]
did not provide bone healing criteria. The detailed criteria
were shown in Table 1.
We defined that evaluated indirect bone healing within
3 months as short time and more than 6 months as long
term.
Delayed fracture union was defined as one or more
clinical symptoms (pain, inability to ambulate, and gait
disorder) at least 6 weeks after surgical repair plus radio-
graphic findings. Fracture nonunion was defined as in-
complete bony bridging through cages in lumbar spine
in 12 months postoperation or no cortices bridging at
the fracture site in more than 8 months postoperation.
The primary outcome was the indirect bone healing
time and fracture nonunion.
Data extraction
Two reviewers independently extracted the data infor-
mation of trial characteristics, patient data, outcome mea-
sures, and study quality using a standardized protocol andlinding Length of follow-up Withdrawal/lost to follow-up (%)
Unclear 12 months 10.8
dequate 12 months 6
dequate 18 months 0
dequate 12 months 0
dequate 12 months 3.0
Unclear 12 months 0
No 6 months 0
dequate 12 months 0
Figure 2 Evaluation of bone healing in short term.
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sensus. To quantify the level of agreement between re-
viewers, a κ statistic was calculated. The κ statistic is a
chance-corrected proportional index, with values ranging
from +1 (perfect agreement) to −1 (complete disagree-
ment). Information extracted included personal informa-
tion, methodology, details on interventions, and reported
outcomes.Study quality assessment
We assessed the methods of every study according to
Cochrane Handbook for Systematic Reviews of Interven-
tions, including reporting of randomization method, al-
location concealment, blinding of outcome assessment,
and completeness of follow-up.Statistical analysis
The meta-analysis was done according to the Cochrane
Collaboration and the Quality of Reporting of Meta-
analyses guidelines (QUOROM) [9] with standard soft-
ware (Review manager (RevMan), version 5.2, Cochrane
collaboration) [10]. Heterogeneity was assessed with I2 sta-
tistics [11]. I2 is the proportion of total variation observed
between the trials attributable to differences between trials
rather than sampling error (chance). Relative risk (RR) was
used as the summary statistic to perform statistical ana-
lysis of dichotomous variables. A fixed effect model was
used for calculations of summary estimates and their 95%
CI. However, when the heterogeneity was significant, a
random effects model was used.Figure 3 Evaluation of bone healing in long term.Results
We identified 916 potentially relevant publications. Eight
trials [3,5,7,12-16] met the predefined inclusion criteria
and were included in our meta-analysis (Figure 1). The
eight trails included 2,508 patients (Table 1). Calcium
supplement was used in three trials [3,7,16]. Three trials
[5,7,15] included patients with distal radial fractures; two
trials [3,13] included patients with posterior lumbar
interbody fusion. Two trials [13,15] included patients with
hip fracture; one trial [14] included patients with tibial
osteotomy.
Six trials [5,7,12-15] compared bisphosphonate with
placebo for indirect bone healing; two trials [3,15] com-
pared different timing of postoperative administrating
bisphosphonate on indirect bone healing.
After adjustment for the agreement between reviewers,
the κ coefficient on the agreement of the included stud-
ies was 0.91 (95% confidence interval 0.82 to 0.94), suggest-
ing good agreement between reviewers in data extraction.
On the basis of quality assessment, five trials were deemed
to be at low risks of bias and the remainder to be at high
risks (Table 2).
Evaluation of bone healing in short term
(within 3 months)
This result was based on two studies [12,14] (138 partici-
pants). Because the examinations of bone healing at
3 months postoperation were heterogeneous among the
included trials, we used a random effects model. The
pooled RR was 1.40; 95% CI (0.36, 5.49). This result was
not statistically significant (P = 0.63) (Figure 2).
Figure 4 Delay bone healing or nonunion of fractures between administrating bisphosphonate groups and control groups.
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6 months)
This result was based on four studies [5,12,13,16] (2,306
participants). The test for homogeneity showed that
results were consistent across trials (P = 0.16, I2 = 42%).
The pooled RR was 1.0; 95% CI (0.98, 1.02). This result
was not statistically significant (P = 0.90) (Figure 3).
Delay bone healing or nonunion of fractures between
administrating bisphosphonate groups and control
groups
Four trials [7,12,13,16] reported delay bone healing or
nonunion of fractures (2,265 participants). The test for
homogeneity showed that results were consistent across
trials (P = 0.21, I2 = 34%). The pooled RR was 0.8; 95%
CI (0.38, 1.69). This result was not statistically significant
(P = 0.55) (Figure 4).
The timing of zoledronic acid infusion on bone healing
Two trials [3,15] compared early (within 1 month of post-
operation) and delay (after 1 month of postoperation)
zoledronic acid infusion on bone healing. The test for
homogeneity showed that results were consistent across
trials (P = 0.38, I2 = 0%). Meta-analysis showed that the
pooled RR was −0.20; 95% CI (−1.03, 0.63). This result
was not statistically significant (P = 0.64) (Figure 5).
Evaluation of bisphosphonate on lumbar fusion
Two studies [12,17] reported zoledronic acid infusion on
lumbar fusion. The test for homogeneity showed that
results were consistent across trials (P = 0.54, I2 = 0%)
in 6 months postoperation but inconsistent across trials
(P = 0.11, I2 = 61%) at 12 months postoperation. Meta-
analysis showed that the pooled RR was 1.35; 95% CIFigure 5 Evaluation of early and delay zoledronic acid infusion on bo(1.11, 1.66) at 6 months postoperation. This result was sta-
tistically significant (P = 0.003). But the pooled RR was
2.80; 95% CI (0.41, 19.24) in 12 months postoperation.
This result was not statistically significant (P = 0.30).
Discussion
The main objective of this meta-analysis was to assess
whether bisphosphonates affect indirect bone healing.
Because in lumbar fusion surgery, bone formation oc-
curs via intramembranous ossification due to the rela-
tively stable construct supporting the fusion site, so our
analysis included spinal fusion. Meta-analysis results
showed that no statistically significant differences were
found in short- and long-term postoperation between
two groups. The delay indirect bone healing or fracture
nonunion was also not significant differences between
two groups. The timing of bisphosphonates infusion did
not affect indirect bone healing. In subgroup analysis,
we found that bisphosphonate-treated groups had statis-
tically significant higher lumbar infusion rate at 6 months
postoperation.
It is still unclear whether bisphosphonates therapy af-
fects indirect bone healing. Several animal studies have
demonstrated that bisphosphonates treatment after sur-
gery would increase callus formation, delay callus re-
modeling, but without influencing the strength of healed
bone or bone healing [16-18]. Van der Poest [7] evalu-
ated whether alendronate prevented bone loss in distal
radius after Colles' fractures. The BMD of distal radius
increased significantly at 3 and 6 months compared with
that of the control group. There were no significant dif-
ferences of anatomic and functional outcomes between
the alendronate group and control group after 1 year
follow-up. In a high tibial osteotomy study, Harding et al.ne healing.
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pin fixation of external fixation but did not affect the bone
healing. Bisphosphonates reduced osteoclast activity, but
more and more clinical results showed that they did not
have advert effects on bone healing.
The timing of infusion bisphosphonates was a contro-
versy. In an animal study, Amanat et al. [19] found that
delayed infusion of zoledronic acid increased more callus
volume compared to both saline and infusion of zoledro-
nic acid immediately at the time of the fracture. However,
our analysis results found that the timing of infusion
bisphosphonate did not affect fracture healing. This was
consistent with Colon-Emeric's report [13]. One possible
reason may be that both included studies involved cancel-
lous bone fractures. The spacious environment for cancel-
lous new bone formation is large enough, so the bone
remodeling process which suppressed by a reduction in
the resorption process by bisphosphonate was not so im-
portant [15]. But the compact bones are different. Fracture
bone debris needs to be absorbed to allow space for new
bone formation [20]. Another reason may be that the dose
of bisphosphonates for treating osteoporosis is sufficient
for affecting bone healing in animal but insufficient for
human.
It is interesting that bisphosphonates affect lumbar
fusion in 6 months after operation in our study. The
consistency across both studies was very well (I2 = 0%).
This may be due to the enough spacious environment for
osteogenesis without absorption process after decompres-
sion of the intervetebral discs. So bisphosphonates may
have particular advantages for shortening intervetebral fu-
sion in osteoporosis patients.
Our meta-analysis also showed that bisphosphonates
did not delay indirect bone healing. Several studies have
shown that the existence of a previous osteoporotic
fracture conferred an approximately twofold higher
risks of subsequent osteoporotic fracture [21]. So more
and more authors recommended pharmacological inter-
vention after first osteoporotic fracture to increase BMD
and reduce the risks of subsequent fractures [22,23].
Health Outcomes and Reduced Incidence with Zoledronic
Acid Once Yearly Recurrent Fracture Trial (HORIZON)
showed that administration of zoledronic acid to patients
with low-energy hip fractures would reduce the risk of
subsequent vertebral or nonvertebral fractures [24].
Our meta-analysis had several limitations. Firstly, our
results are subject to limitations inherent to any meta-
analysis based on pooling of data from different trials with
different doses of drugs, duration, fracture sites, and pa-
tient groups. Secondly, the reporting may be influenced by
expectations of the investigators and patients. The surgical
technique of doctors may also influence the healing re-
sults. Finally, the number of the included studies and par-
ticipants were relatively small.Conclusions
In summary, the available data suggests that bisphospho-
nates do not cause a clinically detectable delay to indirect
bone healing regardless of the timing of bisphosphonate
delivery in relation to the fracture. However, the clinical
studies reviewed are likely to be underpowered.
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